Alec Reynolds

Alec Reynolds is the president and Chief Executive Officer of Expedition Medicines and a Senior Partner at Flagship Pioneering.

Since joining Flagship in 2020, Alec has held several positions, including leading the company’s efforts to expand its global presence and impact and, most recently, as the interim President of Cellarity. Prior to that, Alec was the Chief Operating Officer of Flagship’s drug discovery and development unit, Pioneering Medicines, where he was responsible for building the operations model and portfolio strategy with a focus on delivering innovative therapies for patients.

Prior to joining Flagship, Alec spent more than 12 years at Celgene in senior roles including Corporate Vice President of the Global Project Leadership team. In this role, he was responsible for more than 20 late-stage development projects in hematology-oncology and inflammation-immunology, including six New Drug Applications (NDA) and Biologics License Applications (BLA) which advanced toward submission within a year. Alec was a key figure in Celgene’s growth and was a member of the company’s Development Committee. He previously served as the global project leader for Revlimid in Multiple Myeloma, the company’s $10 billion therapy and helped achieve several key regulatory approvals. Alec was on the founding leadership team of Celgene China and lived in Shanghai for three years building that business. Prior to Celgene, Alec worked at the U.S. Treasury, The Carlyle Group, and Morgan Stanley.

Alec earned his M.B.A. from the University of Virginia Darden School of Business and his A.B. in Politics from Princeton University.